Welcome to our dedicated page for Inhibrx Biosciences news (Ticker: INBX), a resource for investors and traders seeking the latest updates and insights on Inhibrx Biosciences stock.
Inhibrx Biosciences, Inc. reports clinical and corporate updates for a pipeline of biologic therapeutic candidates developed with protein engineering platforms. The company’s programs include ozekibart (INBRX-109), a tetravalent death receptor 5 agonist antibody studied in oncology indications including chondrosarcoma, colorectal cancer and Ewing sarcoma, and INBRX-106, a hexavalent OX40 agonist evaluated in immuno-oncology settings such as head and neck squamous cell carcinoma.
Company developments commonly cover clinical trial data, regulatory submissions and designations, scientific conference presentations, quarterly and annual financial results, and capital resources. Inhibrx Biosciences also carries a completed corporate history tied to its 2024 separation from Inhibrx, Inc. following the sale of the INBRX-101 program.
Inhibrx (Nasdaq: INBX) reported first quarter 2026 results and clinical updates for INBRX-106 and ozekibart (INBRX-109).
Cash was $161.7 million, net loss was $33.4 million ($2.15 per share), and a BLA for ozekibart in conventional chondrosarcoma was submitted to the FDA.
Inhibrx (Nasdaq: INBX) reported interim Phase 2 HexAgon data for INBRX-106 plus pembrolizumab in first-line PD-L1–high HNSCC. In 53 response-evaluable patients, the combination showed a 44.0% confirmed objective response rate versus 21.4% with pembrolizumab alone, including three complete responses versus none in control.
Combination treatment produced up to a 15-fold increase in peripheral CD8+ and CD4+ T-cell proliferation and a manageable safety profile without treatment-related deaths. Progression-free survival data are expected in Q4 2026, with a Phase 3 start planned for Q3 2026 and expansion into NSCLC studies.
Inhibrx (NASDAQ: INBX) will webcast a clinical update on INBRX-106 from the randomized Phase 2 HexAgon study on May 11, 2026, 5:30 a.m. PT. The presentation will report interim results comparing INBRX-106 plus pembrolizumab versus pembrolizumab alone in first-line, PD-L1 positive (CPS ≥20) metastatic or unresectable recurrent HNSCC.
Investors can join via webinar or dial-in; the webcast will be available for 60 days and the corporate presentation will be updated on Inhibrx's website.
Inhibrx (Nasdaq: INBX) reported updated Phase 1/2 interim data for ozekibart (INBRX-109) plus FOLFIRI in late-line colorectal cancer as of April 10, 2026. In 45 evaluable patients the ORR was 20%, median PFS 5.5 months, and DCR 87%; ~42% were progression-free at six months.
The combination showed a manageable safety profile dominated by Grade 1–2 diarrhea, fatigue, and nausea. Inhibrx plans FDA meetings in H2 2026 and submitted a BLA for chondrosarcoma in April 2026.
Inhibrx (Nasdaq: INBX) will webcast a clinical update on ozekibart (INBRX-109) on Tuesday, April 21, 2026 at 1:30 p.m. PT. The presentation covers Phase 1/2 data for ozekibart plus FOLFIRI in locally advanced or metastatic, unresectable colorectal cancer.
Investors can join via webcast or telephone; the presentation will be archived for 60 days and the corporate presentation updated on the Investors page.
Inhibrx (Nasdaq: INBX) reported fourth quarter and fiscal 2025 results on March 19, 2026, highlighting clinical milestones and financials. Cash and cash equivalents were $124.2 million as of December 31, 2025, and the company obtained $75.0 million in loan proceeds on March 18, 2026.
Fiscal 2025 R&D expense was $113.0 million versus $203.7 million in 2024; net loss was $140.1 million for fiscal 2025 versus net income of $1.7 billion in fiscal 2024. Key clinical milestones and trial data readouts are scheduled across 2026, including a planned BLA submission early Q2 2026 for ozekibart.
Inhibrx (Nasdaq: INBX) will present clinical data at the ESMO Sarcoma and Rare Cancers Congress in Lugano, Switzerland, March 12-14, 2026. A mini oral session on March 12 will feature the Phase 1 study of tetravalent DR5 agonist ozekibart (INBRX-109) combined with irinotecan and temozolomide in adolescents and adults with Ewing sarcoma.
Lead author is Rashmi Chugh, M.D.; presenting author is Ana Sebio, M.D., Ph.D. The presentation (abstract 84MO) is scheduled for March 12 at 11:30 am CET in Hall A, Palazzo dei Congressi Lugano, and will be accessible via a link on the company investor website upon commencement.
Inhibrx (Nasdaq: INBX) provided clinical updates on INBRX-106 and ozekibart (INBRX-109) on December 16, 2025. Key progress: INBRX-106 has enrolled 46 of 60 randomized patients in the Phase 2 portion for first-line unresectable/metastatic HNSCC and expects to finish Phase 2 enrollment in Q1 2026. A separate Phase 1/2 checkpoint inhibitor refractory/relapsed NSCLC cohort completed enrollment at 34 patients in November 2025. Current datasets lack maturity to support conclusions; maturity expected in 2H 2026 to inform efficacy versus standard of care.
Ozekibart (INBRX-109) completed enrollment of 44 patients in the FOLFIRI expansion (late-line colorectal cancer); PFS data expected to be mature in Q2 2026. Enrollment for the IRI/TMZ Ewing sarcoma cohort is expected to complete in Q2 2026; if response trends persist, Inhibrx plans an FDA meeting in 2H 2026 to discuss accelerated approval.
Inhibrx (Nasdaq: INBX) reported third quarter 2025 results and clinical updates on November 14, 2025. Ozekibart (INBRX-109) met the registrational trial primary endpoint in chondrosarcoma with a statistically significant improvement in median progression-free survival versus placebo; key secondaries showed improved disease control and quality of life. The company plans to submit a BLA in Q2 2026. Interim expansion-cohort data show high response and disease control rates in colorectal cancer and Ewing sarcoma.
Financials: cash and cash equivalents were $153.1M as of September 30, 2025 (down from $186.6M on June 30, 2025). R&D expense was $28.5M and G&A was $5.3M for Q3 2025. Net loss was $35.3M or $2.28 per share.
Inhibrx (Nasdaq: INBX) announced presentations and a poster at three upcoming scientific conferences in November 2025 covering clinical and preclinical data for the DR5 agonist ozekibart (INBRX-109) and related DR5 clinical results.
Events and highlights:
- Nov 5, 2025 — La Jolla: DR5 agonist clinical data presentation by Josep Garcia, PhD and Katelyn Willis, PhD.
- Nov 14, 2025 — Boca Raton (CTOS): Phase 2 ChonDRAgon randomized registrational results in conventional chondrosarcoma (lead author Robin L. Jones, MD).
- Nov 22, 2025 — Honolulu (SNO): Poster on INBRX-109 anti-tumor activity in GBM models, monotherapy and with TMZ.